On June 10, Abivax S.A. declined 5.27% in regular trading, trading at $97.595/share, with trading volume of $43.897 million. The stock continues to face dual headwinds from drug safety concerns and an emerging legal threat.

The decline stems from unresolved safety controversies surrounding the company's lead drug obefazimod in its Phase 3 maintenance trial for moderately to severely active ulcerative colitis. While the trial met its primary endpoint with efficacy data ranking among the best in class, the 50mg dose group reported cases of prostate cancer, breast cancer, colonic dysplasia, and multiple non-melanoma skin cancers. Wedbush Securities has flagged an elevated risk of a black box warning for obefazimod due to malignancy cases. Additionally, The Schall Law Firm has initiated a securities fraud investigation into the company, focusing on whether it issued false or misleading statements regarding clinical trial results. The combination of safety risks and legal exposure continues to suppress market sentiment. The stock had previously plunged over 40% intraday following the initial data release and has since partially recovered but remains under persistent selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)